Krog Ricki T, de Miranda Noel F C C, Vahrmeijer Alexander L, Kooreman Nigel G
Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Cancers (Basel). 2021 Nov 18;13(22):5789. doi: 10.3390/cancers13225789.
Advances in the treatment of pancreatic ductal adenocarcinoma (PDAC) using neoadjuvant chemoradiotherapy, chemotherapy, and immunotherapy have had minimal impact on the overall survival of patients. A general lack of immunogenic features and a complex tumor microenvironment (TME) are likely culprits for therapy refractoriness in PDAC. Induced pluripotent stem cells (iPSCs) should be explored as a means to advance the treatment options for PDAC, by providing representative in vitro models of pancreatic cancer development. In addition, iPSCs could be used for tailor-made cellular immunotherapies or as a source of tumor-associated antigens in the context of vaccination.
使用新辅助放化疗、化疗和免疫疗法治疗胰腺导管腺癌（PDAC）的进展对患者的总生存期影响甚微。普遍缺乏免疫原性特征和复杂的肿瘤微环境（TME）可能是PDAC治疗难治性的罪魁祸首。诱导多能干细胞（iPSC）应作为一种手段加以探索，通过提供胰腺癌发展的代表性体外模型来推进PDAC的治疗选择。此外，iPSC可用于定制细胞免疫疗法，或在疫苗接种的背景下作为肿瘤相关抗原的来源。
